Anita J. Kumar

529 total citations
37 papers, 245 citations indexed

About

Anita J. Kumar is a scholar working on Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Anita J. Kumar has authored 37 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 13 papers in Public Health, Environmental and Occupational Health and 12 papers in Oncology. Recurrent topics in Anita J. Kumar's work include Lymphoma Diagnosis and Treatment (16 papers), Acute Lymphoblastic Leukemia research (10 papers) and Acute Myeloid Leukemia Research (8 papers). Anita J. Kumar is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Acute Lymphoblastic Leukemia research (10 papers) and Acute Myeloid Leukemia Research (8 papers). Anita J. Kumar collaborates with scholars based in United States, United Kingdom and Israel. Anita J. Kumar's co-authors include Susan K. Parsons, Angie Mae Rodday, Diane Von Ah, Kathryn H. Schmitz, Patricia A. Ganz, Gabriel A. Brooks, Grace Campbell, Andrew M. Evens, Larissa Nekhlyudov and Jonathan W. Friedberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Anita J. Kumar

33 papers receiving 243 citations

Peers

Countries citing papers authored by Anita J. Kumar

Since Specialization

Citations

This map shows the geographic impact of Anita J. Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anita J. Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anita J. Kumar more than expected).

Fields of papers citing papers by Anita J. Kumar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anita J. Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anita J. Kumar. The network helps show where Anita J. Kumar may publish in the future.

Co-authorship network of co-authors of Anita J. Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Anita J. Kumar. A scholar is included among the top collaborators of Anita J. Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anita J. Kumar. Anita J. Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma 2025 ·Haematologica ·(unknown), (unknown), Ellin Berman, Philip Caron, Lorenzo Falchi, Paul A. Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, Anita J. Kumar, Jennifer Kimberly Lue, Alison J. Moskowitz, Colette Owens, Maria Lia Palomba, Parastoo B. Dahi, Gilles Salles, Santosha A. Vardhana, Gunjan L. Shah, Andrew D. Zelenetz, William T. Johnson, Ariela Noy	0
2	Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review 2025 ·Leukemia & lymphoma ·Efrat Luttwak, Anita J. Kumar, Gilles Salles	0
3	Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma 2024 ·JACC CardioOncology ·Jenica Upshaw, Jason Nelson, Benjamin Sweigart, Angie Mae Rodday, Anita J. Kumar, Marvin A. Konstam, John B. Wong, Bonnie Ky, (unknown), Jonathan W. Friedberg, Andrew M. Evens, David M. Kent, Susan K. Parsons	5
4	Prevalent Heart Failure And Cardioprotective Medication Use In Older Individuals With Lymphoma: A SEER-Medicare Analysis 2022 ·Journal of Cardiac Failure ·Jenica Upshaw, Jason Nelson, Anita J. Kumar, Bonnie Ky, Marvin A. Konstam, David M. Kent, (unknown), Susan K. Parsons	1
5	T083: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma 2022 ·HemaSphere ·Jenica Upshaw, Jason Nelson, Angie Mae Rodday, Anita J. Kumar, Andreas K. Klein, Marvin A. Konstam, John B. Wong, Iris Z. Jaffe, Bonnie Ky, Jonathan W. Friedberg, (unknown), David M. Kent, Susan K. Parsons	2
6	Perceptions of Role in Treatment Decision Making and Understanding of Late Effects Among Hodgkin Lymphoma Survivors: Results From a National Survey HL Decision Making and Late Effects 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Anita J. Kumar, (unknown), (unknown), Susan K. Parsons	0
7	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma 2021 ·Haematologica ·Richard J. Lin, Colette Owens, Esther Drill, (unknown), (unknown), (unknown), Ariela Noy, John F. Gerecitano, Pamela Drullinsky, Philip Caron, Anita J. Kumar, Matthew J. Matasar, Craig H. Moskowitz, Beatriz Korc‐Grodzicki, Andrew D. Zelenetz, Gilles Salles, Paul A. Hamlin	4
8	Hodgkin lymphoma survivor perspectives on their engagement in treatment decision-making and discussion of late effects 2021 ·Supportive Care in Cancer ·(unknown), Anita J. Kumar, (unknown), (unknown), (unknown), Susan K. Parsons	2
9	Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy 2021 ·Journal of Geriatric Oncology ·Anita J. Kumar, Jason Nelson, Angie Mae Rodday, Andrew M. Evens, Jonathan W. Friedberg, Tanya M. Wildes, Susan K. Parsons	7
10	Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL) 2020 ·Blood ·Anita J. Kumar, Jason Nelson, Angie Mae Rodday, Andrew M. Evens, Jonathan W. Friedberg, Tanya M. Wildes, Susan K. Parsons	0
11	First‐line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)‐Medicare population‐based study 2020 ·British Journal of Haematology ·Angie Mae Rodday, Theresa Hahn, Anita J. Kumar, Peter K. Lindenauer, Jonathan W. Friedberg, Andrew M. Evens, Susan K. Parsons	12
12	Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens 2019 ·Blood ·Angie Mae Rodday, Theresa Hahn, Anita J. Kumar, Peter K. Lindenauer, Jonathan W. Friedberg, Andrew M. Evens, Susan K. Parsons	1
13	Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper 2019 ·Current Hematologic Malignancy Reports ·Kah Poh Loh, Maya Abdallah, Anita J. Kumar, Nina Rosa Neuendorff, Saurabh Dahiya, Heidi D. Klepin	17
14	Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study 2018 ·Blood ·Anita J. Kumar, (unknown), Angie Mae Rodday, Marlise R. Luskin, Wendy Stock, Susan K. Parsons	1
15	Chemotherapy is administered to a minority of hospitalized patients with diffuse large B-cell lymphoma and is associated with less likelihood of death during hospitalization 2018 ·Cancer Epidemiology ·Anita J. Kumar, (unknown), Angie Mae Rodday, Susan K. Parsons	2
16	The Development and Validation of an Electronic Health Record (EHR)-Based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin Lymphoma (HL) Treated in a US Community Oncology Setting 2018 ·Blood ·Chun Chao, Lanfang Xu, (unknown), Angie Mae Rodday, Joseph Feliciano, Anita J. Kumar, Andrew M. Evens, Susan K. Parsons	1
17	Longer Length of Stay and No Chemotherapy Is Associated with Greater Likelihood of Death during Hospitalization in Patients with Diffuse Large B-Cell Lymphoma: An Analysis from the National Inpatient Sample (NIS) 2017 ·Blood ·Anita J. Kumar, (unknown), Angie Mae Rodday, Susan K. Parsons	1
18	The Utility of the Charlson Comorbidity Index in Predicting Use of Treatment and Survival in Older Lymphoma Patients 2016 ·Blood ·Gunjan L. Shah, Aaron N. Winn, Anita J. Kumar, Miguel‐Angel Perales, Pei‐Jung Lin, Susan K. Parsons	2
19	Comparison of Survival and Costs of Rituximab-Based Chemotherapy for Initial Therapy of Follicular Lymphoma in Elderly Patients 2016 ·Blood ·Gunjan L. Shah, Aaron N. Winn, Pei‐Jung Lin, Anita J. Kumar, Susan K. Parsons	2
20	Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation 2013 ·Biology of Blood and Marrow Transplantation ·Anita J. Kumar, Elizabeth O. Hexner, Noelle V. Frey, Selina M. Luger, Alison W. Loren, Ran Reshef, Jean Boyer, Jacqueline Smith, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, David Porter, Steven C. Goldstein	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact